Fate Therapeutics, Inc.
FATEAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 14, 2026 | Piper Sandler | $8.00(+212%) | $2.56 | TheFly | |
| Aug 14, 2026 | Wells Fargo | $3.50(+39%) | $2.52 | TheFly | |
| Jun 8, 2026 | H.C. Wainwright | Debjit Chattopadhyay | $7.00(+254%) | $1.98 | StreetInsider |
| May 19, 2026 | Jefferies | $4.00(+112%) | $1.89 | TheFly | |
| Mar 6, 2025 | Stifel Nicolaus | $3.00(+188%) | $1.04 | TheFly | |
| Nov 13, 2024 | BMO Capital | Etzer Darout | $5.00(+48%) | $3.37 | StreetInsider |
| Aug 14, 2024 | Stifel Nicolaus | Benjamin Burnett | $5.00(+53%) | $3.27 | StreetInsider |
| Jun 17, 2024 | Piper Sandler | Edward Tenthoff | $6.00(+66%) | $3.60 | StreetInsider |
| May 16, 2024 | H.C. Wainwright | Debjit Chattopadhyay | $5.00(+18%) | $4.24 | StreetInsider |
| May 10, 2024 | Piper Sandler | Edward Tenthoff | $4.00(+3%) | $3.88 | StreetInsider |
| May 10, 2024 | BMO Capital | Etzer Darout | $6.00(+55%) | $3.87 | StreetInsider |
| May 10, 2024 | Canaccord Genuity | Bill Maughan | $9.00(+131%) | $3.90 | TheFly |
| Jan 9, 2023 | Goldman Sachs | $4.00(-9%) | $4.40 | Benzinga | |
| Jan 6, 2023 | Morgan Stanley | $8.00(+90%) | $4.22 | Benzinga | |
| Jan 6, 2023 | Piper Sandler | $12.00(+9%) | $11.00 | Benzinga | |
| Jan 6, 2023 | BMO Capital | $7.00(-36%) | $11.00 | Benzinga | |
| Jan 5, 2023 | Truist Financial | Robyn Karnauskas | $7.00(-36%) | $11.00 | TheFly |
| Dec 15, 2022 | Goldman Sachs | Andrea Tan | $10.00(-35%) | $15.37 | TheFly |
| Dec 13, 2022 | Truist Financial | $46.00(+198%) | $15.46 | Benzinga | |
| Dec 13, 2021 | Oppenheimer | Matthew Biegler | $135.00(+176%) | $48.98 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Wells Fargo | maintain | Equal Weight | Nov 6, 2026 |
| Wedbush | maintain | Outperform | Oct 27, 2026 |
| Wedbush | maintain | Outperform | Aug 14, 2026 |
| Wells Fargo | maintain | Equal Weight | Aug 14, 2026 |
| Piper Sandler | maintain | Overweight | Aug 14, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 8, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 4, 2026 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | Oct 31, 2025 |
| Needham | maintain | Hold | Oct 27, 2025 |
| Wedbush | upgrade | Neutral →Outperform | Oct 27, 2025 |
| Wells Fargo | maintain | Equal Weight | Aug 13, 2025 |
| Needham | maintain | Hold | Jun 12, 2025 |
| Barclays | maintain | Overweight | May 14, 2025 |
| Needham | maintain | Hold | May 14, 2025 |
| Baird | maintain | Neutral | May 14, 2025 |
| Stifel | maintain | Hold | Mar 6, 2025 |
| Wells Fargo | maintain | Equal Weight | Mar 6, 2025 |
| Wedbush | maintain | Neutral | Mar 6, 2025 |
| Needham | maintain | Hold | Mar 6, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Aug 22, 2024 |
| Piper Sandler | upgrade | Neutral →Overweight | Jun 17, 2024 |
| HC Wainwright & Co. | maintain | Neutral | May 16, 2024 |
| Piper Sandler | maintain | Neutral | May 10, 2024 |
| Wedbush | maintain | Neutral | May 10, 2024 |
| BMO Capital | maintain | Market Perform | May 10, 2024 |
Earnings History
Next report: Feb 25, 2027 · EPS est. $-0.29| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.25 | $-0.27 | $1.4M | $1.1M |
| Aug 13, 2026 | $-0.25 | $-0.25 | $2.1M | $1.3M |
| May 13, 2026 | $-0.26 | $-0.29 | $1.3M | $1.5M |
| Feb 26, 2026 | $-0.27 | $-0.27 | $1.4M | $1.3M |
| Nov 13, 2025 | $-0.27 | $-0.29 | $1.7M | $1.2M |
| Aug 12, 2025 | $-0.29 | $-0.35 | $1.9M | $1.1M |
| May 13, 2025 | $-0.32 | $-0.39 | $1.6M | $1.2M |
| Mar 5, 2025 | $-0.44 | $-0.44 | $1.9M | $1.4M |
News
Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be favorable, further supporting RECLAIM-LN
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative and broadly accessible pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on November 2, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 300,000 shares of th…
Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with approximately 50% mean reduction in proteinuria Encouraging safety profile with no dose-limiting toxicities, high-grade CRS, ICANS, GvHD or IEC-HS in autoimmune patients treated with a single dose of FT819; low incidences of infection and cytopenia were also observed Clinical data reinforces the patie…
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on October 1, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 62,900 shares of the Company's common stock …
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in the following investor conferences in the fourth quarter of 2026.
What happened Fate Therapeutics, Inc. (NASDAQ: FATE) said the California Institute for Regenerative Medicine awarded it a $15.0 million CLIN2 grant on September 25, 2026. The grant supports RECLAIM-LN, a Phase 2, potentially registrational trial of FT819 in refractory moderate-to-severe systemic lupus erythematosus with lupus nephritis. RECLAIM-LN, also called FT819-201, is a multicenter, open-label, single-arm
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis
SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disease, today announced that four abstracts from its off-the-shelf CAR T-cell programs have been selected for presentation at the American College of Rheumatology (ACR) Convergence 2026, being held November 6-1…
SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced clinical data from its off-the-shelf anti-CD19 CAR T-cell product candidate FT819, and pre-clinical data from its off-the-shelf anti-CD19 and CD38 CAR T-cell product candidate FT839 wil…
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference, being held September 9–12, 2026 in New York, NY.
BlackRock Inc. acquired a new position in shares of Fate Therapeutics, Inc. (NASDAQ: FATE) in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 7,298,895 shares of the biopharmaceutical company's stock, valued at approximately $19,707,000. BlackRock Inc. owned approximately 6.26% of Fate Therapeutics as of its
Fate Therapeutics has initiated the phase 2 RECLAIM-LN trial of FT819 in lupus nephritis, dosing the first patient in an outpatient setting. FATE plans to open 20 trial sites by the end of 2026 and expects interim analysis data from multiple patients in H2'27, potentially accelerating enrollment. Phase 1 data for FT819 showed reductions in disease activity in systemic lupus erythematosus, including in patients with lupus nephritis.
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites
Fate Therapeutics (FATE) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.29 per share a year ago.
First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day discharge